FBLG Latest Press Releases

-- September 3, 2026 --

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing PRNewswire 8:30 AM

-- September 1, 2026 --

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media PRNewswire 8:30 AM

-- August 27, 2026 --

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PRNewswire 8:31 AM

-- August 26, 2026 --

FibroBiologics Regains Compliance with Nasdaq Trading Rules PRNewswire 8:30 AM

-- August 24, 2026 --

FibroBiologics Appoints Leigh Steinberg to Board of Directors PRNewswire 8:30 AM

-- August 20, 2026 --

FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease PRNewswire 8:30 AM

-- August 18, 2026 --

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints PRNewswire 8:30 AM

-- August 11, 2026 --

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets PRNewswire 8:30 AM

-- August 5, 2026 --

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage PRNewswire 8:30 AM

-- July 31, 2026 --

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate PRNewswire 5:35 PM

-- July 9, 2026 --

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors PRNewswire 8:30 AM

-- July 7, 2026 --

FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial PRNewswire 8:31 AM

-- June 30, 2026 --

FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference PRNewswire 8:30 AM

-- June 29, 2026 --

FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PRNewswire 4:01 PM

-- June 26, 2026 --

FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PRNewswire 8:30 AM

-- June 22, 2026 --

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing Globe Newswire 8:30 AM

-- June 16, 2026 --

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers Globe Newswire 8:30 AM

-- June 3, 2026 --

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers Globe Newswire 7:00 AM

-- May 22, 2026 --

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting Globe Newswire 8:30 AM

-- May 18, 2026 --

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics Globe Newswire 8:30 AM

-- May 11, 2026 --

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus Globe Newswire 8:30 AM

-- May 5, 2026 --

FibroBiologics CEO Issues Letter to Shareholders Globe Newswire 8:30 AM

-- May 4, 2026 --

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring Globe Newswire 4:01 PM

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial Globe Newswire 8:30 AM

-- April 30, 2026 --

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update Globe Newswire 5:55 PM

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 Globe Newswire 8:30 AM

-- April 20, 2026 --

FibroBiologics Compliant with All Nasdaq Listing Requirements Globe Newswire 4:01 PM